Vistagen Therapeutics, Inc.
refisolone
vasomotor symptoms (hot flashes) due to menopause
Date
TBD
Advisory committee · Date TBD estimated
What's at stake
An FDA advisory committee reviews refisolone for vasomotor symptoms (hot flashes) due to menopause around Date TBD. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 8-K
verified 14h ago
“Received FDA “Study May Proceed” clearance under an Investigational New Drug (IND) application to support further clinical development of refisolone in the United States as a potential rapid-onset, hormone-free, and non-systemic treatment o”